Sanofi $SNY Shares Bought by Ritholtz Wealth Management

Ritholtz Wealth Management increased its position in Sanofi (NASDAQ:SNY) by 48.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,685 shares of the company’s stock after purchasing an additional 14,880 shares during the period. Ritholtz Wealth Management’s holdings in Sanofi were worth $1,884,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Western Wealth Management LLC acquired a new stake in Sanofi in the 1st quarter valued at $29,000. Root Financial Partners LLC acquired a new position in Sanofi during the third quarter worth $27,000. Signature Equity Partners LLC raised its holdings in Sanofi by 322.2% during the third quarter. Signature Equity Partners LLC now owns 857 shares of the company’s stock worth $35,000 after buying an additional 654 shares during the last quarter. Financial Network Wealth Advisors LLC lifted its stake in shares of Sanofi by 103.3% in the third quarter. Financial Network Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $38,000 after buying an additional 463 shares in the last quarter. Finally, Provenance Wealth Advisors LLC lifted its stake in shares of Sanofi by 359.8% in the third quarter. Provenance Wealth Advisors LLC now owns 2,322 shares of the company’s stock valued at $96,000 after buying an additional 1,817 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SNY shares. HSBC reiterated a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. UBS Group restated a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Thursday, October 1st. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a research note on Tuesday, September 29th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $53.00.

Sanofi Stock Down 0.2%

NASDAQ SNY traded down $0.09 on Friday, reaching $48.37. The company had a trading volume of 1,675,700 shares, compared to its average volume of 4,657,690. The stock has a market capitalization of $117.27 billion, a P/E ratio of 23.95, a P/E/G ratio of 1.33 and a beta of 0.31. The company’s fifty day moving average is $42.68 and its 200 day moving average is $44.38. Sanofi has a 52-week low of $39.07 and a 52-week high of $52.67. The company has a quick ratio of 0.27, a current ratio of 1.12 and a debt-to-equity ratio of 0.20.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 30th. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.56 by $0.48. The business had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The business’s revenue was up 16.2% on a year-over-year basis. During the same period last year, the business earned $2.91 EPS. Sell-side analysts anticipate that Sanofi will post 5.07 earnings per share for the current fiscal year.

About Sanofi

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.